Law
Offices of Howard G. Smith reminds investors of the upcoming January
18, 2016 deadline to file a lead plaintiff motion in the class
action filed on behalf of investors who purchased Clovis Oncology, Inc.
(“Clovis” or the “Company”) (NASDAQ: CLVS)
securities between October 31, 2013 and November 13, 2015, inclusive
(the “Class Period”). Investors who suffered losses on their investment
in Clovis securities are encouraged to contact the Law Offices of Howard
G. Smith to discuss their legal rights.
Clovis is a biopharmaceutical company that focuses on acquiring,
developing, and commercializing innovative anti-cancer agents in the
United States, Europe and additional international markets.
The complaint filed on behalf of shareholders alleges that throughout
the Class Period, Defendants made false and/or misleading statements, as
well as failed to disclose material adverse facts about the Company’s
business, operations, and prospects. Specifically, Defendants made false
and/or misleading statements and/or failed to disclose: (1) that the New
Drug Application (“NDA”) that Clovis submitted to the FDA for
rociletinib contained immature data sets based on both unconfirmed
response rates and confirmed response rates; (2) that Clovis’
Breakthrough Therapy designation submission contained immature data set
based primarily on unconfirmed responses; (3) that Clovis presented
interim data publicly and at medical meetings that included a data set
based primarily on unconfirmed responses; (4) that as the efficacy data
matured, the number of patients with an unconfirmed response who
converted to a confirmed response was lower than expected; (5) that, as
a result of the foregoing, Clovis’ NDA was likely to be delayed and/or
rejected by the FDA; and (6) that, as a result of the foregoing, the
Defendants’ statements about Clovis’ business, operations, and
prospects, were false and misleading and/or lacked a reasonable basis.
If you purchased Clovis shares, you may move the Court no later than January
18, 2016 to request appointment as lead plaintiff. To be a member of
the class you need not take any action at this time; you may retain
counsel of your choice or take no action and remain an absent member of
the Class. If you wish to learn more about this action, or if you have
any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Howard G. Smith, Esquire,
of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free
at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com,
or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151211005646/en/
Copyright Business Wire 2015